Potent, Selective, and Orally Bioavailable Quinazoline-Based STK17A/B Dual Inhibitors

Sana Chaudhry,Jesus R. Castro,Tulasigeri M. Totiger,Jumana Afaghani,Rabia Khurshid,Miah Nicholls,Ziming Zhang,Stephan C. Schürer,Ashish Shah,Justin Taylor,Yangbo Feng

DOI: https://doi.org/10.1021/acsmedchemlett.4c00125

2024-06-19

ACS Medicinal Chemistry Letters

Abstract:STK17A is a novel uncharacterized member of the death-associated protein family of serine and threonine kinases. Overexpression of STK17A is observed in many cancers. We identified a lead compound that is based on a quinazoline core. Optimizations of the lead compound led to the discovery of potent and selective STK17A/B inhibitors with drug-like properties and oral bioavailability. Compound 9 had an STK17A inhibitory IC(50) of 23 nM. Based on profiling studies against two wild-type kinase...

chemistry, medicinal